TICKERNERD
Menu
BAXBAXHealthcare · Medical Instruments & Supplies

BAX Stock Forecast: Baxter International, Inc. Price Predictions for 2026-2027

Last close, 5 Oct 2026
$24
+3.11% on the day

The 13 Wall Street analysts covering Baxter International, Inc. hold a median 12-month price target of $28 — +15.6% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 90 of 100 as at 3 Oct 2026 — among the strongest tenth. Here, the model and the Street point the same way.

Market cap
$12.1B
Ticker Nerd rank
90 / 100
Median analyst target
$28
Analysts covering
13
Revenue$3.0B+5.3% y/y
Operating income$217.0M
Net income$126.0M
Free cash flow$166.0M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
+3.1%
1M
−6.2%
YTD
+26.9%
1Y
+1.7%
From 52W high
−14.5%
From 52W low
+53.4%
$16
$28
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

BAX stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Baxter International, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 3 Oct 2026
90 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Value
96
Accruals
95
Revisions
92
Issuance
86
Volatility
59
Growth
59
Quality
48
Momentum
47
Size
14

Value (96): The shares cost little relative to the profits and assets behind them — which can mean the market is too gloomy, or that the business really is in trouble.

Momentum (47): The shares have been drifting down relative to others.

Size (14): Larger than most of the companies we track — more scrutinised, less often mispriced.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

BAX stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on BAX, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$15$20$25$30$35$40Jan 26Apr 26Jul 26Oct 26BAXHigh $40Median $28Low $23

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says13 analysts
2 Buy11 Hold0 Sell
Low $23Median $28High $40

The green dot is the last close — the median target sits +15.6% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 9 moved their price target up and 0 moved it down.

DateFirmActionRatingTarget
31 July 2026CitigroupUpgradeNeutral$17 → $28
31 July 2026StifelMaintainsHold$24 → $28
31 July 2026TD CowenMaintainsHold$24 → $29
31 July 2026Wells FargoMaintainsEqual-Weight$19 → $23
28 July 2026StifelMaintainsHold$19 → $24
28 July 2026UBSMaintainsNeutral$19 → $25
27 July 2026TD CowenMaintainsHold$20 → $24
15 July 2026Goldman SachsMaintainsNeutral$19 → $21
15 July 2026Goldman SachsMaintainsNeutral—
6 July 2026Evercore ISI GroupMaintainsOutperform$22 → $24
6 July 2026Evercore ISI GroupMaintainsOutperform—
28 May 2026CitigroupDowngradeSell—
4 May 2026BarclaysMaintainsOverweight—
6 Apr 2026Evercore ISI GroupMaintainsOutperform—
11 Mar 2026CitigroupMaintainsNeutral—
17 Feb 2026Goldman SachsMaintainsNeutral—
13 Feb 2026BarclaysMaintainsOverweight—
9 Jan 2026BarclaysMaintainsOverweight—
2 Dec 2025Morgan StanleyMaintainsUnderweight—
31 Oct 2025Argus ResearchDowngradeHold—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. BAX appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

BAX vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 5 Oct 2026, Baxter International, Inc. returned +1.7% against +16.2% for the S&P 500, dividends included.

BAX vs S&P 500, last 12 monthsTotal return, rebased to 100
708090100110120Jan 26Apr 26Jul 26Oct 26BAXS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

BAX analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
EPS revision, 90 days
+6.8%
Analysts raising
12
Analysts cutting
0
Fundamentals

Baxter International, Inc. (BAX) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
86.3×

Cheaper than 8% of US stocks

Price / sales
1.1×

Cheaper than 67% of US stocks

Price / book
2.0×

Cheaper than 45% of US stocks

EV / EBITDA
10.4×

Cheaper than 36% of US stocks

Growth & margins
Revenue growth (YoY)
5.3%

Higher than 40% of US stocks

Earnings growth (YoY)
38.5%

Higher than 71% of US stocks

Gross margin
34.9%

Higher than 42% of US stocks

Operating margin
14.4%

Higher than 72% of US stocks

Net margin
−9.3%

Higher than 20% of US stocks

Returns & dividend
Return on equity
−14.4%

Higher than 34% of US stocks

Return on assets
2.8%

Higher than 64% of US stocks

Dividend yield
0.2%

Higher than 40% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Baxter International, Inc. (BAX) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Baxter International, Inc. has a market value of $12.1B and an enterprise value of $19.6B.

  • Revenue in the twelve months to 30 June 2026: $11.5B. The latest quarter grew 5.3% year on year.

  • Net income over the same four quarters: −$1.1B, a −9.3% net margin.

  • Diluted earnings per share, trailing twelve months: $−2.07.

  • Free cash flow in the twelve months to 30 June 2026: $812.0M, after $504.0M of capital spending.

  • Baxter International, Inc. spent $184.0M on dividends in the twelve months to 30 June 2026.

  • Shares outstanding: 517.0M.

  • Trailing P/E: 86.3×; forward P/E: 11.5× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Forward dividend yield: 0.17%, paying out 155% of earnings.

  • Baxter International, Inc. employs 37,500 people — $306K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 5 Oct 2026

Data provided by Twelve Data

Peers

BAX vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelMedical Instruments & Supplies
CompanyMarket capTKN rank
BAXBaxter International, Inc.$12.1B
90
COOThe Cooper Cos., Inc.$11.2B
71
AVTRAvantor, Inc.$10.5B
82
ALGNAlign Technology, Inc.$10.3B
84
RGENRepligen Corp.$10.2B
92
SOLVSolventum Corp.$15.2B
92
ATRAptarGroup, Inc.$7.9B
51

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Baxter International, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest BAX news & analysis

Baxter Releases Inaugural Connected Hospital Report

Business Wire · 30 Sept 2026neutral

Baxter announced the release of its inaugural 2026 Connected Hospital Report, based on a survey of 150 information technology and nursing leaders, examining how US hospitals are leveraging technology investments to improve clinical and operational outcomes. The report outlines how hospitals are progressing along a "connected hospital" journey by identifying four distinct stages.

Why it matters — This report signals Baxter's thought leadership and visibility in healthcare technology and connected-hospital solutions, a growth area relevant to BAX's medtech portfolio.

Why Investors Need to Take Advantage of These 2 Medical Stocks Now

Zacks Investment Research · 29 Sept 2026neutral

Zacks Investment Research highlights two medical stocks that investors may want to consider, noting that the Zacks Earnings ESP is a useful tool for identifying potential earnings surprises. The article urges investors to take advantage of these opportunities now.

Why it matters — BAX watchers may gain insight into how earnings-surprise signals and sector attention could relate to the broader medical-stock landscape in which Baxter operates.

Here's Why You Should Retain Baxter Stock in Your Portfolio for Now

Zacks Investment Research · 24 Sept 2026neutral

Zacks Investment Research recommends retaining Baxter stock, citing support from the company's portfolio reset and growth in connected care and advanced surgery. The report notes that margins, the Novum IQ product, and China pricing remain ongoing risks.

Why it matters — A Baxter watcher would care because the report weighs the company's strategic portfolio changes and growth areas against persistent margin, product, and pricing concerns that could affect near-term performance.

BAX Raises 2026 Outlook as Strong Q2 Growth Offsets Margin Pressure

Zacks Investment Research · 7 Sept 2026positive

Baxter raised its 2026 sales and earnings outlook after strong second-quarter growth. Manufacturing costs, tariffs, and pricing pressures are noted as factors pressuring margins.

Why it matters — A BAX watcher would care because the raised 2026 outlook signals confidence in continued revenue growth, even as cost and tariff pressures could weigh on profitability.

FAQ

Frequently asked questions about BAX stock

What is the BAX stock price forecast for 2026-2027?

The 13 Wall Street analysts covering Baxter International, Inc. have a median 12-month price target of $28, with estimates ranging from $23 to $40. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is BAX stock a buy right now?

Of the 13 analysts covering Baxter International, Inc., 2 rate it a Buy, 11 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Baxter International, Inc. 90 out of 100 across roughly 4,600 US stocks as at 3 Oct 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank BAX?

As at 3 Oct 2026, Baxter International, Inc. ranks 90 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Value (96 of 100).

Will BAX stock go up?

No one can know that. What the data says: the median 12-month target from 13 analysts implies +15.6% from the last close, and Ticker Nerd's factor model ranks Baxter International, Inc. 90 out of 100 as at 3 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the BAX stock forecast for 2030?

No analyst covering Baxter International, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for BAX are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $23 to $40 over the next 12 months.

How has BAX stock performed over the past year?

Baxter International, Inc. returned +1.7% over the 12 months to 5 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Baxter International, Inc. do?

Baxter International Inc. is a global healthcare company focused on providing essential medical products and technologies used in hospitals, clinics, surgery centers, pharmacies, and home-care settings.

What is the latest news on BAX?

The most recent item we track (Business Wire, 30 Sept 2026): "Baxter Releases Inaugural Connected Hospital Report". Baxter announced the release of its inaugural 2026 Connected Hospital Report, based on a survey of 150 information technology and nursing leaders, examining how US hospitals are leveraging technology investments to improve clinical and operational outcomes. The report outlines how hospitals are progressing along a "connected hospital" journey by identifying four distinct stages.

Company

About Baxter International, Inc.

Baxter International Inc. is a global healthcare company focused on providing essential medical products and technologies used in hospitals, clinics, surgery centers, pharmacies, and home-care settings. Baxter International Inc. develops and supplies infusion systems, sterile intravenous solutions, injectable pharmaceuticals, parenteral nutrition therapies, advanced surgery products, patient monitoring and diagnostic technologies, smart beds, and respiratory care devices. The company also supports renal and acute care through therapies and connected solutions that help clinicians deliver treatment across a wide range of care environments. Its portfolio is designed to support everyday healthcare delivery, from critical care and procedural settings to long-term and ambulatory care. Baxter International Inc. plays an important role in the medical technology market by supplying products that are widely used in routine treatment, life-sustaining therapy, and hospital infrastructure.

CEO Mr. Andrew P. Hider · 37,500 employees · United States · https://www.baxter.com